冠状动脉微血管疾病诊断与治疗的研究进展  

Research Progress in Diagnosis and Treatment of Coronary Microvascular Diseases

作　　者：胡牵 张锦[2] HU Qian;ZHANG Jin(The First Clinical Medical College of Lanzhou University,Lanzhou 730000,China;Department of Cardiology,the First Hospital of Lanzhou University/Gansu Key Laboratory of Cardiovascular Diseases,Lanzhou 730000,China)

机构地区：[1]兰州大学第一临床医学院,兰州730000 [2]兰州大学第一医院心血管内科甘肃省心血管疾病重点实验室,兰州730000

出　　处：《医学综述》2020年第17期3444-3450,共7页Medical Recapitulate

摘　　要：冠状动脉微血管疾病是影响冠状动脉微循环结构和(或)功能的一类疾病,其中冠状动脉微血管功能障碍(CMD)是心肌缺血的重要发病机制之一。CMD可广泛存在于具有心血管疾病高危因素的患者人群中,且与不良心血管事件的风险增加有关。近年来循证医学和介入性心脏病学迅速发展,使得CMD受到人们的高度重视。随着心肌缺血诊断技术的发展以及对冠状动脉微循环结构和功能障碍研究的深入,临床实践中CMD的检出率不断提高。虽然目前一些现有的抗心绞痛药物可能对治疗有帮助,但CMD的精准治疗仍是主要挑战。Coronary microvascular disease is a kind of disease that affects the structure and/or function of coronary microcirculation,and coronary microvascular dysfunction(CMD)is one of the important pathogenesis of myocardial ischemia.CMD extensively exists in patients with high risk factors for cardiovascular disease and is associated with an increased risk of adverse cardiovascular events.In recent years,with the rapid development of evidence-based medicine and interventional cardiology,CMD has been paid much attention.With the development of myocardial ischemia diagnosis techniques and the in-depth study of coronary microcirculation structure and dysfunction,the detection rate of CMD in clinical practice has been increasing.While some existing anti-angina medications may be helpful,the precise treatment of CMD remains a major challenge.

关 键 词：冠状动脉微血管功能障碍 冠状动脉血流储备 微血管功能评估 药物治疗 

分 类 号：R541.4[医药卫生—心血管疾病]